J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Sitavig (TN)

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

132 API Suppliers, 33 USDMF, 19 CEP/COS, 8 JDMF, 16 EU WC, 36 KDMF, 26 NDC API, 52 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

402 FDF Dossiers, 98 FDA Orange Book, 122 Europe, 17 Canada, 19 Australia, 30 South Africa, 116 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 5%;1%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 6 SPI Pharma, 11 DKSH, 6 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 36 BASF, 3 Corel Pharma Chem, 6 DFE Pharma, 2 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures, 4 Ingredion Pharma Solutions, 22 Kerry, 1 Kima Chemical, 3 Lonza Capsugel, 14 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 3 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 1 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

67 Fillers, Diluents & Binders, 39 Disintegrants & Superdisintegrants, 37 Thickeners and Stabilizers, 28 Direct Compression, 27 Granulation, 26 Topical, 23 Coating Systems & Additives, 23 Solubilizers, 18 Film Formers & Plasticizers, 16 Controlled & Modified Release, 16 Lubricants & Glidants, 16 Co-Processed Excipients, 12 Parenteral, 12 Taste Masking, 11 Chewable & Orodispersible Aids, 8 Empty Capsules, 8 Emulsifying Agents, 6 Rheology Modifiers, 3 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Soft Gelatin, 1 API Stability Enhancers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 49 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 113 Regulatory FDF Prices

MARKET PLACE

41 APIs, 23 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 1 US Exclusivities, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 12 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
28/06/2025	TAPI Technology & API Services	Israel	TEVA PHARMACEUTICAL INDUSTRIES LTD Tel Aviv - Jaffa IL	CEP 1997-084 - Rev 12	Aciclovir	2024-05-30	Valid	Chemical		968
28/06/2025	ABC Farmaceutici SpA	Italy	ABC Farmaceutici S.p.A. Torino IT	R1-CEP 1997-125 - Rev 04	Aciclovir	2011-03-15	Withdrawn by Holder	Chemical	2013-10-11	968

Sitavig (TN)

Sitavig (TN)

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

132 API Suppliers

33 USDMF

19 CEP/COS

8 JDMF

16 EU WC

36 KDMF

26 NDC API

52 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

7 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

402 FDF Dossiers

98 FDA Orange Book

122 Europe

17 Canada

19 Australia

30 South Africa

116 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CREAM;TOPICAL - 5%;1%

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Rochem International Inc

6 SPI Pharma

11 DKSH

6 Faran Shimi Pharmaceutical

5 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

4 ACG Worldwide

5 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

36 BASF

3 Corel Pharma Chem

6 DFE Pharma

2 Esteem Industries

2 Finar

9 Gangwal Chemicals

1 Ideal Cures

4 Ingredion Pharma Solutions

22 Kerry

1 Kima Chemical

3 Lonza Capsugel

14 Microlex e.U

2 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

2 Novo Excipients

4 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

3 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

4 Silverline Chemicals

1 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

4 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

CAPSULE;ORAL - 200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUSPENSION;ORAL - 200MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 800MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons